Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 5, 2010, Pages 653-672

  Liutkus, Mélanie ^a   Caijo, Frédéric ^a,b,c   Girard, Anne Lise ^b   Ayral, Erwan ^a   Audinot, Valérie ^d   Boutin, Jean A ^e   Renard, Pierre ^d   Caignard, Daniel Henri ^d   Dacquet, Catherine ^d   Ktorza, Alain ^d   Mosset, Paul ^b,c   Grée, René ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIV RENNES   (France)

^c UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^d INSTITUT DE RECHERCHES SERVIER   (France)

^e INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

3 chloro 2 quinolinecarboxaldehyde; Benzoquinoline; Dual agonists; PPARs; Quinoline

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 8 HYDROXYARACHIDONIC ACID; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; QUINOLINE; REGAGLITAZAR; S 70655; TESAGLITAZAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG SYNTHESIS; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GENES, REPORTER; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPOGLYCEMIC AGENTS; KINETICS; METABOLIC SYNDROME X; OCTANOIC ACIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; QUINOLINES; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTIONAL ACTIVATION;

EID: 77956027846     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903468171     Document Type: Article

References (18)

1. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
2. Stumvoll M, Golstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-1346
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
4. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093
5. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004;25: 331-336
6. Göttlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992;89:4653-4657
7. Leff T, Reed JE. The antidiabetic PPARγ ligands: an update on compounds in development. Curr Med Chem Imunol Endocr Metab Agents 2002;2:33-47.
8. Henke BR. Peroxisome proliferator-activated receptor alpha/beta dual agonists for the treatment of type 2 diabetes. J Med Chem 2004;47: 4118-4127
9. Rubenstrunk A, Hanf R, Hum DW, Fruchart J-C, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-1081
10. Fiévet C, Fruchart J-C, Staels B. PPARγ and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006;6:606-614
11. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21: 687-710.
12. Caijo F, Mosset P, Grée R, Audinot-Bouchez V, Boutin J, Renard P, et al. Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs. Bioorg Med Chem Lett 2005;15:4421-4426
13. Caijo F, Mosset P, Grée R, Audinot-Bouchez V, Boutin J, Renard P, et al. Synthesis of aromatic analogs of 8(S)-HETE and their biological evaluation as activators of the PPAR nuclear receptors. Eur J Org Chem 2006:2181-2196
14. Kerry MA, Boyd GW, Mackay SP, Meth-Cohn O, Platt L. The synthesis of benzo[h]quinolines as topoisomerase inhibitors. J Chem Soc Perkin Trans 1 1999:2315-2321
15. Ferry G, Bruneau V, Beauverger P, Goussard M, Rodriguez M, Lamamy VO, et al. Binding of prostaglandins to human PPARγ: tool assessment and new natural ligands. Eur J Pharmacol 2001;417: 77-89.
16. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARγ but not by PPARγ activators. Nature 1998;393:790-793
17. Grée R, Liutkus M, Caijo F, Brioche J, Jennequin T, Dacquet C, et al. Preparation of heterocycles, in particular 3-[(alkynyl)(hydroxy)methyl]-2- phenylalkoxyquinolines, pharmaceutical compositions containing them, and their use in the treatment of type II diabetes and obesity. PCT Int. Appl. WO/2008/081096. Geneva: WIPO, 2008.
18. Liutkus M, Dacquet C, Audinot-Bouchez V, Boutin J, Caignard D-H, Ktorza A, et al. Synthesis of a novel series of 8-HETE analogs and their biological evaluation towards the PPAR nuclear receptors. Lett Drug Des Discov 2008;5:503-511